Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM4 phase 3 trial of oral CP101 for prevention of recurrent Clostridioides difficile infection
MOH_2022-09-20_012063Phase 3Not yet recruiting
- Sponsor
- Finch Therapeutics
- Start
- Jul 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CP101 in Clostridioides difficile colitis (CDI) (3 arms), sponsored by Finch Therapeutics. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
CP101
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on MOH_2022-09-20_012063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-20_012063.